These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38002585)

  • 21. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
    Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
    Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma.
    Trovisco V; Soares P; Soares R; Magalhães J; Sá-Couto P; Sobrinho-Simões M
    Hum Pathol; 2005 Jun; 36(6):694-7. PubMed ID: 16021577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
    Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
    Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.
    Park JY; Kim WY; Hwang TS; Lee SS; Kim H; Han HS; Lim SD; Kim WS; Yoo YB; Park KS
    Endocr Pathol; 2013 Jun; 24(2):69-76. PubMed ID: 23625203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of
    Yu L; Ma L; Tu Q; Zhang YI; Chen Y; Yu D; Yang S
    Oncol Lett; 2015 Jun; 9(6):2633-2638. PubMed ID: 26137119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
    Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
    Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
    Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.
    Torregrossa L; Viola D; Sensi E; Giordano M; Piaggi P; Romei C; Materazzi G; Miccoli P; Elisei R; Basolo F
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4413-4420. PubMed ID: 27571181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
    Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.